Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes

Trial Profile

Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 22 Sep 2017 Primary endpoint has been met. (Functional HDL-C) as per results published in the Circulation Journal
    • 22 Sep 2017 Results published in the Circulation Journal
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top